Skip to content

Provide Point-of-Contact

Opportunity

Clinical trial participants may have many questions and concerns during and after the clinical trial. To help address participants’ questions / concerns in a timely manner, support (e.g., phone number to call, in-app support, virtual bot) can allow clinical trial participants to receive answers and reassurance without needing to wait for the next scheduled visit. 

Considerations to Help Action the Opportunity

  • Partner with investigative sites to ensure understanding of currently available site contact support and what support sites may need to enable flexibility
  • Identify multiple options for a participant to contact / stay engaged with the investigative site or reach out to a designated contact
  • Provide a clear description of which service should be used in each situation and point of contact, if several service options are available
  • Offer service(s) in the participant’s native language and make them available 24/7
  • Partner with participants / patient organizations to ensure support services are easy to use and fit their needs​
  • Provide tools and training to enable participant self service 

Value and Potential Benefits

  • Allows participants to ask questions regarding clinical trial participation when needed, potentially alleviating concerns at the current time rather than waiting for next visit
  • May increase participant engagement by allowing stronger connectivity between participants and clinical trial staff

Tools and Resources

  • No tools or resources currently available to support this opportunity

Related Blog Posts

Solving the Clinical Trial Data Problem

In a new LinkedIn article, Janice Chang, CEO of TransCelerate, and Nicholas Brooke, CEO of The Synergist & PFMD, outline how efforts like the Clinical Trial Data Network, supported by TransCelerate through technical expertise and industry-vetted solutions from our Digital Data Flow initiative, aim to make clinical trial information more structured, connected, and accessible across…

The Clinical Trial Enterprise: Can AI Fix It?

Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle.  Read the full article by Rob DiCicco from Drug Discovery News here.